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Abstract
Background: Pertussis or whooping cough is an acute respiratory illness caused by the Gram-negative pathogen
Bordetella pertussis. Despite high vaccination coverage whooping cough is currently re-emerging in many developed
countries. Although the causes of pertussis resurgence are matter of debate, emerging evidences suggest that acellular
vaccines efficiently protect against the hallmark symptoms of pertussis disease but fail to prevent colonization. This
presumably impacts on increased risk of bacterial transmission and consequent spread throughout the population.
These evidences suggest that improved vaccines may be required for efficient bacterial clearance in the upper
respiratory tract. Consequently, there is a need for novel bioassays to evaluate at pre-clinical or clinical level the
impact of different vaccines on B. pertussis colonization.
Results: We developed a high-throughput bacterial adhesion inhibition (BAI) assay based on human respiratory cell
lines and on live bacteria chemically conjugated to a fluorescent dye. Employing A549 cells as model, we evaluated the
impact of antibodies elicited by acellular (aP) and whole cell (wP) vaccines on B. pertussis adhesion in vitro. Moreover,
we settled the method also on polarized Calu-3 cells grown at air-liquid interface (ALI), showing that this assay can be
extended to more complex cell models mimicking the airway epithelium.
Conclusions: We proved that this method is a sensitive, rapid and reproducible system to evaluate the anti-adhesive
properties of vaccine-induced antibodies and can be employed to assess improved pertussis vaccines.
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Background
Pertussis or whooping cough is an acute respiratory
disease caused by Bordetella pertussis [1]. Despite high
vaccination coverage, pertussis is a re-emerging disease
causing mortality in infants worldwide, mainly in deve-
loping countries, but also at increasing incidence in many
developed countries [2, 3]. While pertussis resurgence is
likely caused by multiple factors [4–7], it is becoming
increasingly evident that currently licensed acellular
pertussis (aP) vaccines are suboptimal in inducing long
lasting protection and in preventing colonization. This pre-
sumably has an impact on increased risk of transmission
and consequent bacterial spread throughout the population.
Recent studies in a nonhuman primate model support
this hypothesis, demonstrating that aP vaccines efficiently
protect against the hallmark symptoms of pertussis
disease but fail to prevent colonization [8].
Improvement of current pertussis vaccines or develop-
ment of novel vaccines should take these findings into
consideration [9] and be effective in shortening bacterial
colonization besides preventing the disease.
Hurdles for the development of improved vaccines
addressing these issues are the lack of pre-clinical tools,
such as serological bioassays and adequate animal models,
suitable to evaluate bacterial adherence and clearance.
The mouse aerosol challenge model, as well as other small
animal models, has been useful in dissecting the mecha-
nisms of pathogenesis of B. pertussis [10]. However, being
B. pertussis an obligate human pathogen, these animal
models are unable to reproduce the full spectrum of
disease in humans. The recently developed baboon model
[11] provides an excellent tool to improve our knowledge
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on B. pertussis transmission and to explore the effect of the
vaccine-induced immunity on colonization and disease
manifestations. However, ethical concerns and high costs
limit the use of baboon model for vaccine antigen screen-
ing, although it is the model of choice for evaluation of
advanced vaccine formulation. Accordingly, new in vitro
bioassays mimicking the natural site of infection of B.
pertussis could represent a valid screening method to test
the functionality of vaccine-induced antibodies in inhibiting
the bacterial adhesion.
One of the mechanisms to control the bacterial burden
is the presence of functional antibodies at the epithelial
barrier which could inhibit the attachment of bacteria
to the respiratory epithelium and the initiation of
colonization. Adhesion assays employing cell models
representing the human respiratory tract have been exten-
sively used to study the mechanisms of B. pertussis adhe-
sion [12–15]. These studies allowed the identification of
the key adhesins involved in the colonization process by
the use of mutant strains or by inhibition with antibodies
targeting individual virulence factors. However, the adhe-
sion assays employed so far were generally based on bac-
terial colony counting or microscopic examinations which
are time-consuming and inadequate for extensive com-
parative analysis of the kinetics of bacterial adhesion.
To overcome the limitations of conventional adhesion as-
says and compare the adhesion inhibitory properties of
vaccine-induced antibodies, a quantitative assay compa-
tible with high-throughput methodologies is then needed.
We report here the development of a new assay to
quantify the adhesion of B. pertussis to airway epithelial
cells and show the efficiency of this method in evaluat-
ing the ability of the antibodies induced by different per-
tussis vaccine formulations to inhibit bacterial adhesion.
Results and discussion
Analysis of fluorescent bacteria
B. pertussis bacteria were labeled with a fluorescent dye
(Alexa Fluor® 488 Carboxylic Acid, Succinimidyl Ester),
which conjugates to the primary amines (R-NH2) of
amine-containing molecules on bacterial surface. After
incubation with the Alexa Fluor® 488, bacteria were washed
to remove unbound dye. To assess whether the conjugation
affected bacterial viability, bacteria were plated after the
conjugation, and the colonies were compared to uncon-
jugated bacteria as control. Colony forming unit (CFU)
counting demonstrated that viability of labeled and un-
labeled bacteria was comparable and that the survival is
maintained after two hours incubation in cell medium
(Fig. 1a). Moreover, all bacteria were efficiently labeled as
shown by fluorescent microscopy examination (Fig. 1b).
Fluorescent bacteria can be quantified by a multi-plate
fluorescent reader, overcoming the limitations of con-
ventional colony counting. To test the sensitivity of the
method and to determine the minimum number of bac-
teria that could be detected by the fluorescence reader,
bacteria were serially diluted and each bacterial suspen-
sion was measured for fluorescence emission and plated
for colony counting.
Figure 2 shows a linear relationship between the num-
ber of bacteria and fluorescence and establishes that the
minimum number of bacteria that could be detected by
the reader is in the range of 103 CFU.
Development of a high-throughput adhesion assay for B.
pertussis
We set up a high-throughput B. pertussis adhesion assay
to determine the level of adhesion of B. pertussis to the
human alveolar epithelial cell line A549. We infected cells
Fig. 1 Effect of fluorescent labeling on B. pertussis viability. a Conjugation of B. pertussis Tohama I with Alexa Fluor® 488 was performed as
described in Materials and Methods. After washes, bacteria were suspended in PBS. Bacterial suspension was serially diluted and plated on
BG agar plates immediately after labeling (blue), and 2 h (red) after incubation at 37 °C. Results represent mean ± SD from a representative
experiment performed in triplicates. b Labeled bacteria were fixed (green) and stained with DAPI (blue) for confocal microscopy analysis
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for 1 h with serially diluted B. pertussis Tohama I strain
and after washes we measured the fluorescence of cell-
adherent bacteria (Fig. 3a). Infected cells were subse-
quently treated with a detergent to release bound bacteria,
and the number of cell-associated bacteria was deter-
mined by CFU counting and compared to the bacterial
suspension at time zero (Fig. 3b). The results show that
the measurement of bacteria-associated fluorescence was
as sensitive as the conventional CFU counting in detecting
the number of adherent bacteria.
Importantly, the presence of the fluorescent dye on
the bacterial surface did not alter the adhesive properties
of B. pertussis as demonstrated by comparing the level of
adhesion of both labeled and unlabeled bacteria (Fig. 3c).
To evaluate the sensitivity of the assay in measuring the
adhesiveness of bacteria to epithelial cells, we analyzed
the contribution of the major adhesins of B. pertussis:
filamentous hemagglutinin (FHA) and pertactin (PRN).
We measured the adhesion of BP536-derivative mutant
strains BP102 and BBC42, defective in FHA and PRN
respectively. As expected these mutants were significantly
less adhesive than the wild-type parental strain. The lack
of FHA protein determined 75.2 % reduction in bacterial
adhesion after 1 h infection on A549 cells, while the lack
of PRN caused a 46 % decrease (Fig. 4a). These results
were confirmed by confocal microscopy (Fig. 4b).
These data suggest that this assay represents a sensitive
and automated quantification of adherent bacteria, and
that it can be applied to compare the adhesive properties
of different strains or evaluate the contribution of indivi-
dual adhesins through the analysis of the relative knock-
out strains.
We further extended the method to a physiological 2D
airway cell model by the use of Calu-3 cells grown on
membrane supports at air-liquid interface. This cell
model is characterized by distinctive columnar polarized
cells and tight junctions (Fig. 5a), reproducing the fea-
tures of functional human airway epithelium [16]. We
infected polarized Calu-3 cells with B. pertussis Tohama
I strain and verified the association of bacteria on the
apical cell surface by confocal microscopy (Fig. 5a). After
growing the cells on microplate membrane supports, we
measured the level of adhesion by the previously de-
scribed high-throughput method, determining the kin-
etic of association of fluorescent bacteria to this airway
cell model (Fig. 5b).
Inhibition of B. pertussis adhesion by vaccine-induced
antibodies
A relevant application of this high-throughput adhesion
assay is the evaluation of the ability of vaccine-induced
antibodies to inhibit B. pertussis adhesion in vitro. Indeed,
functional antibodies induced by vaccination may provide
protection by several mechanisms, one of which is pre-
venting bacterial adhesion to airway epithelial cells.
We considered in this study the ability of mouse anti-
bodies induced by acellular (aP) and whole cell (wP)
vaccines to inhibit adhesion of Tohama I strain to A549
cells. Fluorescent bacteria were pre-incubated with mouse
pooled sera in a range of eight dilutions and A549 cells
were infected as described before (Fig. 6a). We found that
even though both aP and wP-induced antibodies interfere
with bacterial attachment to epithelial cells, they showed
different kinetics of inhibition (Fig. 6b): anti-wP serum
showed a substantial reduction of adhering bacteria even
at low serum concentrations, while anti-aP serum was ef-
fective in inhibiting only at the highest concentrations.
Pre-immune serum and serum from unvaccinated animals
Fig. 2 Standard curve showing the relationship between
bacteria-associated fluorescence and number of bacteria. Labeling
of B. pertussis Tohama I with Alexa Fluor® 488 was performed as
described in Materials and Methods. Fluorescent bacteria were
suspended in PBS to reach OD600 0.2 and then 2-fold serially diluted.
For each dilution, 100 μL of bacterial suspension were transferred in
triplicates in a 96-well plate and fluorescence was assessed at 485/
535 nm by a multi-well fluorescent reader, while 100 μL were serially
diluted and plated on BG agar plates in triplicates for CFU counting.
Results represent mean ± SD from one out of the two representative
experiments performed in triplicates
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were included in the experiments as negative control. We
also measured the inhibitory effect of sera from individual
mice (single serum dilution indicated in the dashed area
of Fig. 6b), showing the consistency of the functional im-
mune response in all animals vaccinated with aP and wP
vaccines (Fig. 6c).
Overall, this assay allowed to determine the range of
serum dilutions effective in inhibiting B. pertussis adhe-
sion to epithelial cells and underlined the contribution
of antigens included in aP vaccines in comparison to the
entire membrane repertoire targeted by wP vaccines.
Conclusions
This novel quantitative adhesion assay offers the possibi-
lity to analyze the functionality of vaccine-induced
antibodies in inhibiting the bacterial adhesion to the host
cells.
Considering the human-restricted host range of B.
pertussis, the use of human cells resembling the air-
way mucosa is a valuable in vitro system to comple-
ment the studies in animal models. Moreover, in the
perspective of limiting the use of animal testing, it is
opportune to encourage and implement the develop-
ment of methods in compliance with the 3Rs
guidelines.
This assay is a sensitive, rapid and reproducible method
to evaluate the capability of vaccine-induced antibodies to
prevent bacterial adhesion and answer to the need of new
pre-clinical tools to predict the impact of different vac-
cines on B. pertussis colonization.
Fig. 3 Adhesion of labeled B. pertussis Tohama I on A549 cells. a A549 cells were infected for 1 h with serially diluted labeled bacteria starting from an
optical density (OD600) of 0.2. After washes, cell-associated bacteria were quantified by fluorescence reading at Ex/Em 485/535 nm. b After fluorescence
reading, infected cells were treated with 1 % saponin, and lysates were serially diluted and plated for CFU counting of adhering bacteria ( ). Aliquots
of serially diluted bacterial suspensions used for infection were also plated ( ) c A549 cells were infected with unlabeled and labeled B. pertussis
Tohama I at OD600 0.2 for 1 h. Adhering bacteria were quantified by CFU counting as described before. Results represent mean ± SD from one out of
the three representative experiments performed in triplicates
Fig. 4 Contribution of FHA and PRN in B. pertussis adhesion to A549 cells. a A549 cells were infected with labeled B. pertussis strains BP536 (wild-type),
BP102 (Δfha) and BBC42 (Δprn) at OD600 0.1 for 1 h. After washes, cell-associated bacteria were quantified by fluorescence reading at Ex/Em 485/
535 nm. Experiments were done in triplicates and data represent mean ± SD. b Adhesion assay was performed as described in A. Infected cells were
fixed and actin (phalloidin, red) and nuclei (DAPI, blue) were stained for confocal microscopy analysis. Images are 3D view of Z-stack acquisition. Results
represent mean ± SD from a representative experiment performed in triplicates
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Fig. 5 Adhesion of labeled B. pertussis Tohama I on polarized Calu-3 cells at air-liquid interface. a Polarized Calu-3 cells were infected with labeled B.
pertussis Tohama I at OD600 0.4 for 1 h. After extensive washes, infected cells were fixed and tight junctions (ZO-1, red) and nuclei (DAPI, blue) were
stained for confocal microscopy analysis. Images are 3D view of Z-stack acquisition. b Polarized Calu-3 cells were infected for 1 h with serially diluted
labeled bacteria starting from an OD600 of 0.4. After washes, cell-associated bacteria were quantified by fluorescence reading at Ex/Em 485/535 nm.
Results represent mean ± SD from a representative experiment performed in triplicates
Fig. 6 Impact of vaccine-induced antibodies on B. pertussis adhesion to A549 cells. a Schematic representation of the assay. b Sera from mice vaccinated
with an acellular pertussis vaccine (aP) and a whole cell pertussis vaccine (wP) (8 mice/group) were pooled, serially diluted in infection medium and
incubated with labeled wild-type B. pertussis Tohama I for 1 h. Pre-immune sera and sera from unvaccinated mice were used as negative control.
A549 cells were then infected with the bacteria/sera mixtures for 1 h and, after extensive washes to remove unbound bacteria, cell-associated bacteria
were quantified by fluorescence reading at Ex/Em 485/535 nm. Results represent mean ± SD from there independent experiments each performed in
triplicates. c Sera from individual mice vaccinated with aP and wP vaccines (8 mice/group) were diluted 1 to 80 and adhesion assay was performed as
described in B. Sera from unvaccinated individual mice were used as negative control. Results represent mean ± SD from a single experiment performed
in triplicates; ****P< 0.0001, **P< 0.01
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Methods
Bacterial strains and growth conditions
The following B. pertussis strains were used in this study:
Tohama I, BP536 [17], fha- and prn- derivative of BP536
(BP102 BBC42 in [18]). Bacteria were stored at −80 °C
and recovered by plating on Bordet-Gengou (BG) agar
plates, supplemented with 15 % sheep blood, for 3 days at
37 °C. Bacteria were then inoculated at initial 600 nm
optical density (OD600) of 0.05–0.1 in Stainer-Scholte
medium supplemented with 0.4 % (w/v) L-cysteine mono-
hydrochloride, 0.1 % (w/v) FeSO4, 0.2 % (w/v) ascorbic
acid, 0.04 % (w/v) nicotinic acid, 1 % (w/v) glutathione.
Cultures were grown in rotary shakers at 37 °C for about
16 h.
Sera
BALB/c mice (8 female/ group, 6-week-old) (Charles River
Laboratories International Inc., Wilmington, MA) received
two intramuscular immunizations, with a 4 weeks interval,
with 100 μL (50 μL /leg) of Boostrix (GSK) and wP vaccine
(NIBSC), both at one fifth of a human dose. Sera were
collected before the vaccination and 2 weeks after the
second immunization. Control unvaccinated mice were
included in the experiments.
Fluorescent labeling of bacteria
Alexa Fluor® 488 Carboxylic Acid, Succinimidyl Ester
(Molecular Probes, Life Technologies) was dissolved in
DMSO, aliquoted for single-use and stocked at −80 °C.
Bacteria were grown for 16 h in liquid culture. Bacteria
were then pelleted at 8000 ×g for 5 min and resuspended
in Dulbecco-PBS (D-PBS) at OD600 0.5. A volume of
445 μL of bacterial suspension was then mixed with 50 μL
NaHCO3 1 M and 5 μL of Alexa Fluor® 488 and incubated
for 15 min at 37 °C. After centrifugation at 8000 ×g for
5 min at room temperature, supernatant was removed
and pellet was washed once with 1 mL PBS to remove
unbound dye. Labeled bacteria were finally collected by
centrifugation at 8000 ×g for 5 min and suspended in
D-PBS at OD600 0.2. Labeled bacteria were then 2-fold
serially diluted in D-PBS and 100 μL of each bacterial
dilution were transferred in triplicates in a black 96-well
plate. Bacteria-associated fluorescence was assessed at
485/535 nm by a multi-well fluorescent reader.
The same bacterial suspensions were further serially di-
luted and plated on BG agar plates in triplicates for colony
forming unit (CFU) counting.
Cell cultures
Cells were grown at 37 °C in humidified atmosphere
containing 5 % CO2.
A549 cell line (Human epithelial alveolar basal adeno-
carcinoma, ATCC CCL-185) was maintained in Ham’s
F-12K medium (Life Technologies) supplemented with
10 % heat-inactivated fetal bovine serum (FBS, Gibco) and
antibiotics.
Calu-3 cells (Human epithelial bronchial adenocarci-
noma, ATCC HTB-55) were maintained in DMEM/F12
medium (Life Technologies) supplemented with 10 %
heat-inactivated FBS and antibiotics.
In order to obtain a polarized epithelium, Calu-3 cells
were cultured on HTS Transwell® 96-well permeable
supports with 1 μm pore polyester membrane (Corning),
previously coated with a 0.03 mg/mL rat tail collagen
type I solution. Cells were seeded at density of 5x105cells/
cm2 (according to [16]) in the apical chamber and cell
medium was added in the basal chamber. Once cells
reached confluence, medium was removed and replaced
only in the basal chamber, and cells were cultured at
air-liquid interface (ALI) for the next 10–14 days.
During ALI culture, basal medium was replaced every
2 days.
High-throughput adhesion assay
A549 cells were seeded on black 96-well plate (2.5x104/
well) and cultured for 1 day in absence of antibiotic. After
fluorescent labeling, bacteria were suspended in F12-K
medium OD600 0.2. Bacteria were then serially diluted and
100 μL of each bacterial dilution was transferred in trip-
licates on plated A549 cells or on polarized Calu-3 cells.
Infected cells were incubated for 1 h at 37 °C. After exten-
sive washing to remove unbound bacteria, fluorescence was
measured at excitation/emission 485/535 nm by Tecan
Infinite F200PRO microplate reader.
To perform the serum-mediated BAI assay, pooled
mouse sera were two-fold serially diluted in F-12K medium
containing 1 % naïve mouse serum and pre-incubated with
fluorescent bacteria for 1 h at 37 °C. To check the inhi-
bitory activity of sera from individual mice, sera were ana-
lyzed at the single dilution of 1:80 and incubated with
fluorescent bacteria as described before. The mixtures bac-
teria/sera were then added to cells; plates were centrifuged
at 500 ×g for 5 min to synchronize the bacterial attachment
and incubated for 1 h at 37 °C. After extensive washing, the
cell-associated fluorescence was measured as described
before.
In control experiments, after fluorescence reading,
infected cells were lysed with 1 % saponin (Sigma) di-
luted in F-12K medium and solubilized bacteria were
serially diluted and plated on BG agar plates for CFU
counting.
Immunofluorescence of fluorescent bacteria
After fluorescent labeling, bacteria were pelleted by centri-
fugation at 8000 ×g for 5 min and fixed in 3.7 % formalde-
hyde (Sigma) for 20 min. After multiple washes, bacteria
were air dried on a poly-L-lysine coated glass slide.
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Samples were mounted with a drop of ProLong® Gold
Antifade Mountant with DAPI (Molecular Probes, Life
Technologies) and analyzed with Zeiss LSM710 confocal
microscope.
Qualitative analysis of bacterial adhesion by
immunofluorescence
A549 cells were seeded on chamber slides coated with
collagen I (5x104/ well) and cultured for 1 day in absence
of antibiotic, while Calu-3 cells were cultured at ALI for
10–14 days, as described previously.
A549 cells and ALI cultured Calu-3 cells were incubated
with fluorescent bacteria as described in the previous
paragraph. After washes, A549 cells were fixed with 3.7 %
formaldehyde (Sigma) for 20 min and were then incubated
with Alexa Fluor® 568 phalloidin (Molecular Probes, Life
Technologies) diluted 1:400 in PBS + 0.1 % Tween20 +
1 % BSA for 30 min. Calu-3 cells were fixed directly on in-
serts by adding 3.7 % paraformaldehyde in the apical and
basal chamber and were then permeabilized with 0.2 %
Triton X-100 diluted in PBS for 5 min. Subsequently, sam-
ples were blocked with PBS containing 3 % Bovine Serum
Albumin (BSA) (Sigma) for 15 min and incubated with
rabbit ZO-1 polyclonal antibodies diluted in PBS + 1 %
BSA (1:200) for 1 h. After washes, samples were incubated
with Alexa Fluor® 568 goat anti-rabbit IgG (1:500) (Mo-
lecular Probes) for 30 min. After three washes with PBS,
the insert was carefully detached by a scalpel and mounted
on a microscope slide by adding one drop of ProLong®
Gold Antifade Mountant with DAPI. Images were ana-
lyzed with Zeiss LSM710 confocal microscope.
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